← Back to Screener
CDT Equity Inc. Warrant (CDTTW)
Price$0.01
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-9.89%
Price vs S&P 500 (4W)66.68%
VGM Score53.48
All Metrics
Price vs S&P 500 (YTD)75.41%
10-Day Avg Trading Volume0.04M
3-Month Avg Trading Volume0.04M
52-Week High$0.02
26-Week Price Return-1.96%
13-Week Price Return35.14%
3-Month Return Std Dev338.80%
Year-to-Date Return81.82%
5-Day Price Return-9.09%
Month-to-Date Return-49.49%
Price vs S&P 500 (13W)26.88%
Beta3.12x
52-Week Low$0.01
mGradeC
vgmGradeC
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CDTTWCDT Equity Inc. Warrant | — | — | C | $0.01 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
CDT Equity Inc is a clinical-stage biopharmaceutical company developing treatments for unmet medical needs with a focus on autoimmune diseases and male infertility. Its lead program is a glucokinase activator in Phase II development for conditions including uveitis, Hashimoto's Thyroiditis, preterm labor, and transplant rejection. The company also has an early-stage MPO inhibitor program targeting idiopathic male infertility.